Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ll six assessment periods, including Week 72, in CAPACITY 2, and at all four of the assessment periods through Week 48 in CAPACITY 1, but not at Week 72. An analysis of pooled data from the two CAPACITY studies showed that placebo-treated patients experienced a mean of 76 mL more decline in FVC than patients who received pirfenidone at Week 72. At Week 48, patients who received pirfenidone experienced a mean of 169 mL less FVC decline compared to placebo in CAPACITY 2 (p=0.002) and a mean of 54 mL less FVC decline in CAPACITY 1 (p=0.006). This pattern of change is consistent with that observed at Week 52 in the Phase 3 study of pirfenidone conducted by Shionogi.

Categorical Analysis of Change in Six-Minute Walk Test (6MWT) Distance

Post-hoc analyses of data from the 826-patient INSPIRE trial suggested that patients experiencing a 50-meter decrement in distance walked during the 6MWT at six months had an approximately 2.5-fold increased risk in mortality. Using this threshold, 33% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 1 (p=0.013), and 37% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 2 (p=0.032) experienced this magnitude of change. In a pooled analysis, 35% and 47% of pirfenidone and placebo patients, respectively, experienced a change that exceeded this threshold (p=0.001).

Safety and Tolerability Results

Safety data presented for both studies showed that pirfenidone given as 2403 mg per day was safe and generally well tolerated. In CAPACITY 2, 83% and 90% of surviving, lung transplant-free patients completed therapy per protocol in the pirfenidone and placebo groups, respectively, and 82% and 90%, respectively, of patients did so in CAPACITY 1. The percentage of patients discontinuing treatment due to an adverse event across both studies combined was 15% and 9% in the pirfenidone and placebo groups, respectively.

'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

6

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013 ... investigating potential claims on behalf of purchasers of ... the "Company") (NasdaqGS: AMAG -News).  The investigation focuses ... federal securities laws. On May 22, ... during intraday trading after the company announced in ...
(Date:5/22/2013)... , May 22, 2013   Accuray Incorporated ... management is scheduled to present at the 2013 Jefferies ... on Thursday, June 6, 2013 at 1:30 p.m. ... the presentation will be available online from the Investor ... The webcast replay of the presentation will ...
(Date:5/22/2013)... and MUNICH , May 22, 2013 ... and marketer of transcatheter aortic valve implantation (TAVI) systems for ... interim results of the J enaValve Eval U ation ... n Pa T ients with S E vere Ao R ... . JUPITER is a post-market registry to evaluate five-year ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4
... Holdings, Inc. (OTCQB: ABHI), a leader in the development ... that it has signed an agreement with a major ... technology product set in its urinalysis product line. ... Adapter/Dongle to be licensed for use in the manufacturer,s ...
... Caliper Life Sciences, Inc. (NASDAQ: CALP ) today ... of the Customer Owner,s Group (COG) meeting to be held ... will webcast a separate Investor Breakout Session from 3:00 - ... investor portion of the conference will feature a presentation by ...
Cached Medicine Technology:Major Medical Diagnostics Manufacturer Signs Agreement to Use AmbiCom Wireless Solution in Its Urinalysis Product Line 2Major Medical Diagnostics Manufacturer Signs Agreement to Use AmbiCom Wireless Solution in Its Urinalysis Product Line 3Caliper Life Sciences to Webcast Investor Session of Open House 2
(Date:5/22/2013)... York (PRWEB) May 22, 2013 Phelps ... established the Westchester Lung Nodule Center for individuals ... receive lung cancer care. Lung cancer is the deadliest form ... more people in the U.S. die from lung cancer than ... with all cancers, early detection increases survival rates. It ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 HR ... event, hosted at the Gwinnett County Fairgrounds, on Friday ... company before, they far surpassed expectations; raising over $6,300 ... corporate sponsor for the event, donating the first $3,000 ... Beesley , challenged the internal staff to match the ...
(Date:5/22/2013)... May 22, 2013 Go Classy the ... announced the launch of their newest website http://www.Desire-Mexico.com ... of like minds, Desire Resorts have become the premier ... a feeling of total liberation while allowing you to ... COO of Go Classy Tours / Caribbean-Hideaways. He goes ...
(Date:5/22/2013)... News) -- In the aftermath of this week,s deadly tornado, ... for children and relatives, but also their pets. ... disaster and relocating to temporary housing can be stressful, but ... tips on how to ease that transition. One smart ... that can be used to help identify any animals displaced ...
Breaking Medicine News(10 mins):Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2Health News:Simple Steps Can Protect Pets in Weather Disasters 2
... , WEDNESDAY, May 26 (HealthDay News) -- Researchers report that ... the brain in mice -- a finding that could help ... who suffer from Alzheimer,s disease and stroke. , Removing clots ... blood to flow unimpeded, since blockages can lead to a ...
... Complete Genomics Inc., a third-generation human genome sequencing ... member of the Roche Group (SIX: RO, ROG; OTCQX: ... to sequence and compare a patient,s primary lung tumor ... researchers to compare the patient,s genome before and after ...
... are reporting development of a fast, simple, inexpensive method ... may cause skin allergies in people -- a method ... appears in ACS, Chemical Research in Toxicology , ... colleagues note the existence of public sentiment against the ...
... dramatically increased survival in the small group of patients who ... findings will be presented at the annual meeting of the ... June 4-8 in Chicago. Mayo oncologists say this new ... this rare cancer seems to be confined to the neck. ...
... undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning ... possible adverse side effects on oral health, according to a ... the American Dental Association (JADA). , Use of bisphosphonates ... osteonecrosis of the jaw (BON) that occurs spontaneously or after ...
... ... Center has become the first Community of Respect™ Medical Center in the Anti-Defamation ... ... Medical Center has become the first Community of Respect™ Medical Center in the ...
Cached Medicine News:Health News:Brain Cells May Serve as Clot-Busters 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
... Oscors proprietary quadripolar pacing ... consistent pacing and sensing in ... combining two bipolar wires in ... for the atrium and ventricle ...
... The TME 227 T ... used for temporary cardiac pacing ... open-heart surgery. The TME 227 ... in the myocardium, which allows ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: